Adverse events after first and second doses of COVID-19 vaccination in England: a national vaccine surveillance platform self-controlled case series study
CONCLUSIONS: COVID-19 vaccines are associated with a small decrease in the incidence of medically attended AEIs. Sentinel networks could routinely report common AEI rates, which could contribute to reporting vaccine safety.PMID:37921538 | DOI:10.1177/01410768231205430 (Source: J R Soc Med AND (has...)
Source: J R Soc Med AND (has... - November 3, 2023 Category: General Medicine Authors: Ruby Sm Tsang Utkarsh Agrawal Mark Joy Rachel Byford Chris Robertson Sneha N Anand William Hinton Nikhil Mayor Debasish Kar John Williams William Victor Ashley Akbari Declan T Bradley Siobhan Murphy Dermot O'Reilly Rhiannon K Owen Antony Chuter Jillian Be Source Type: research
Adverse events after first and second doses of COVID-19 vaccination in England: a national vaccine surveillance platform self-controlled case series study
CONCLUSIONS: COVID-19 vaccines are associated with a small decrease in the incidence of medically attended AEIs. Sentinel networks could routinely report common AEI rates, which could contribute to reporting vaccine safety.PMID:37921538 | DOI:10.1177/01410768231205430 (Source: J R Soc Med AND (has...)
Source: J R Soc Med AND (has... - November 3, 2023 Category: General Medicine Authors: Ruby Sm Tsang Utkarsh Agrawal Mark Joy Rachel Byford Chris Robertson Sneha N Anand William Hinton Nikhil Mayor Debasish Kar John Williams William Victor Ashley Akbari Declan T Bradley Siobhan Murphy Dermot O'Reilly Rhiannon K Owen Antony Chuter Jillian Be Source Type: research
Efficacy of Oxford-AstraZeneca (ChAdOx1 CoV-19) vaccine against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) cases, hospital admissions, type of variants, and deaths
CONCLUSIONS: The efficacy of the Oxford-AstraZeneca COVID-19 vaccine against symptomatic COVID-19 cases, various variants, ICU, and emergency admissions, and against deaths was high. The present study results provide valuable insights for healthcare workers, policymakers, and researchers about the precise efficacy levels against symptomatic cases, hospitalization, and mortality across the diverse populations and age groups.PMID:37916383 | DOI:10.26355/eurrev_202310_34193 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - November 2, 2023 Category: Drugs & Pharmacology Authors: S A Meo S Aftab N M Bayoumy A S Meo Source Type: research
Efficacy of Oxford-AstraZeneca (ChAdOx1 CoV-19) vaccine against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) cases, hospital admissions, type of variants, and deaths
CONCLUSIONS: The efficacy of the Oxford-AstraZeneca COVID-19 vaccine against symptomatic COVID-19 cases, various variants, ICU, and emergency admissions, and against deaths was high. The present study results provide valuable insights for healthcare workers, policymakers, and researchers about the precise efficacy levels against symptomatic cases, hospitalization, and mortality across the diverse populations and age groups.PMID:37916383 | DOI:10.26355/eurrev_202310_34193 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - November 2, 2023 Category: Drugs & Pharmacology Authors: S A Meo S Aftab N M Bayoumy A S Meo Source Type: research
Efficacy of Oxford-AstraZeneca (ChAdOx1 CoV-19) vaccine against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) cases, hospital admissions, type of variants, and deaths
CONCLUSIONS: The efficacy of the Oxford-AstraZeneca COVID-19 vaccine against symptomatic COVID-19 cases, various variants, ICU, and emergency admissions, and against deaths was high. The present study results provide valuable insights for healthcare workers, policymakers, and researchers about the precise efficacy levels against symptomatic cases, hospitalization, and mortality across the diverse populations and age groups.PMID:37916383 | DOI:10.26355/eurrev_202310_34193 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - November 2, 2023 Category: Drugs & Pharmacology Authors: S A Meo S Aftab N M Bayoumy A S Meo Source Type: research
IgG antibody levels against the SARS-CoV-2 spike protein in mother –child dyads after COVID-19 vaccination
ConclusionsCOVID-19 mRNA vaccines induce high anti-SARS-CoV-2 S titers in pregnant women, which can inhibit the binding of ACE2 to protein S and are efficiently transferred to the fetus. However, there was a rapid decrease in antibody levels at 2 to 3 months post-partum, particularly in infants. (Source: Infection)
Source: Infection - October 28, 2023 Category: Infectious Diseases Source Type: research
